Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer-Reference-Cited by-同舟云学术

Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer

Published:2020-06-07 Issue:20 Volume:27 Page:3271-3289
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Cámara-Quílez María¹,Barreiro-Alonso Aida¹,Rodríguez-Bemonte Esther¹,Quindós-Varela María²,Cerdán M. Esperanza¹,Lamas-Maceiras Mónica¹

Affiliation:

1. EXPRELA Group, Centro de Investigacions Cientificas Avanzadas (CICA), Departamento de Bioloxia. Facultade de Ciencias, INIBIC- Universidade da Coruna, Campus de A Zapateira, 15071, A Coruna, Spain

2. Translational Cancer Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Carretera del Pasaje s/n, 15006 A Coruña, Spain

Abstract

We have summarized common and differential functions of HMGB1 and HMGB2 proteins with reference to pathological processes, with a special focus on cancer. Currently, several “omic” approaches help us compare the relative expression of these 2 proteins in healthy and cancerous human specimens, as well as in a wide range of cancer-derived cell lines, or in fetal versus adult cells. Molecules that interfere with HMGB1 functions, though through different mechanisms, have been extensively tested as therapeutic agents in animal models in recent years, and their effects are summarized. The review concludes with a discussion on the perspectives of HMGB molecules as targets in prostate and ovarian cancers.

Funder

Co-funded by European Regional Development Fund

Xunta de Galicia

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference131 articles.

1. Barreiro-Alonso A.; Lamas-Maceiras M.; Rodríguez-Belmonte E.; Vizoso-Vázquez Á.; Quindós M.; Cerdán M.E.; High mobility group B Proteins, their partners, and other redox sensors in ovarian and prostate cancer. Oxid Med Cell Longev 2016,2016

2. Cohen J.; Negroni R.; Gaggiolo M.; Apropos of a case of meningeal cryptococcosis cured with amphoterin B. Rev Asoc Med Argent 1964,78,547-552

3. Ugrinova I.; Pasheva E.; HMGB1 Protein: A therapeutic target inside and outside the cell. Adv Protein Chem Struct Biol 2017,107,37-76

4. Das D.; Peterson R.C.; Scovell W.M.; High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol 2004,18(11),2616-2632

5. Joshi S.R.; Ghattamaneni R.B.; Scovell W.M.; Expanding the paradigm for estrogen receptor binding and transcriptional activation. Mol Endocrinol 2011,25(6),980-994

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlation of serum HMGB1 and HMGB2 levels with clinical symptoms in allergic rhinitis children;Medicine;2023-09-15

2. Structure and Functions of HMGB2 Protein;International Journal of Molecular Sciences;2023-05-05

3. Serum HMGB1 levels and its clinical significance in elderly patients with intertrochanteric fractures after intramedullary fixation surgery;Medicine;2023-02-22

4. The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance;Molecular and Cellular Biochemistry;2021-01-11

5. Role of Serum HMGB1 in Prostate Cancer;European Journal of Therapeutics;2020-06-29